Mucosa-associated Lymphoid Tissue (MALT) Lymphoma - Pipeline Insight, 2021

DelveInsights, Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Pipeline Insight, 2021, report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Mucosa-associated Lymphoid Tissue (MALT) Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Understanding
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Overview
MALT lymphoma belongs to a group of non-Hodgkin lymphomas called marginal zone lymphomas. It is a low grade (slow growing) non-Hodgkin lymphoma (NHL) that starts in the mucosa which lines some body organs and cavities. MALT lymphoma can affect people of any age but it typically develops in people in their mid-60s. MALT lymphoma is more common in people who have been infected with certain viruses or who have particular autoimmune conditions. The symptoms of MALT lymphoma depend on where the lymphoma develops. Unlike many other types of lymphoma, MALT lymphoma develops outside the lymph nodes. It does not usually cause swollen lymph nodes. People with MALT lymphoma very rarely experience B symptoms. MALT lymphoma is usually diagnosed by removing a sample of tissue and looking at it under a microscope. This involves a small operation called a biopsy, which is usually done under a local anaesthetic. Surgery is used very occasionally if the lymphoma is only affecting one part of body and is in an area where it can be safely removed.

"Mucosa-associated Lymphoid Tissue (MALT) Lymphoma - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Mucosa-associated Lymphoid Tissue (MALT) Lymphoma pipeline landscape is provided which includes the disease overview and Mucosa-associated Lymphoid Tissue (MALT) Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Mucosa-associated Lymphoid Tissue (MALT) Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mucosa-associated Lymphoid Tissue (MALT) Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Mucosa-associated Lymphoid Tissue (MALT) Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Mucosa-associated Lymphoid Tissue (MALT) Lymphoma.

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Emerging Drugs Chapters
This segment of the Mucosa-associated Lymphoid Tissue (MALT) Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Emerging Drugs
Tafasitamab: Morphosys
Tafasitamab (MOR208, formerly Xmab5574) is an investigational monoclonal antibody directed against the antigen CD19 which is broadly expressed on the surface of B cells. It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkins lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas like follicular lymphoma (FL) and marginal zone lymphomas (MZL), as well as chronic lymphocytic leukemia (CLL). In January 2020, MorphoSys and Incyte entered into a collaboration and licensing agreement to further develop and commercialize tafasitamab globally. The InMIND Study is a Phase III double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R follicular lymphoma (FL) Grade 1 to 3a or R/R marginal zone lymphoma (MZL).

Zandelisib/ MEI Pharma
Zandelisib is being evaluated in multiple clinical studies, including COASTAL, a Phase III study, and TIDAL, a Phase II study, both of which are evaluating zandelisib in patients with relapsed and refractory follicular and marginal zone lymphomas. The development and planned commercialization of zandelisib is being conducted in partnership with Kyowa Kirin Co., Ltd. (KKC). MEI and KKC will co-develop and co-promote zandelisib in the U.S., with MEI recording all revenue from U.S. sales. KKC has exclusive commercialization rights outside of the U.S. COASTAL is intended to support full marketing applications in the U.S. and globally in relapsed or refractory follicular lymphoma and marginal zone lymphoma patients who have received at least one prior line of treatment. COASTAL is also intended to act as the required confirmatory study for the potential U.S. accelerated approval of zandelisib based on the TIDAL study. FDA has granted zandelisib Fast Track designation.
Further product details are provided in the report..

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Mucosa-associated Lymphoid Tissue (MALT) Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Mucosa-associated Lymphoid Tissue (MALT) Lymphoma
There are approx. 8+ key companies which are developing the therapies for Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. The companies which have their Mucosa-associated Lymphoid Tissue (MALT) Lymphoma drug candidates in the most advanced stage, i.e. Phase III include, Morphosys.
Phases
DelveInsights report covers around 8+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical.
Molecule Type

Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mucosa-associated Lymphoid Tissue (MALT) Lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mucosa-associated Lymphoid Tissue (MALT) Lymphoma drugs.

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Report Insights
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Mucosa-associated Lymphoid Tissue (MALT) Lymphoma drugs?
How many Mucosa-associated Lymphoid Tissue (MALT) Lymphoma drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Mucosa-associated Lymphoid Tissue (MALT) Lymphoma?
What are the key collaborations (IndustryIndustry, IndustryAcademia), Mergers and acquisitions, licensing activities related to the Mucosa-associated Lymphoid Tissue (MALT) Lymphoma therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Mucosa-associated Lymphoid Tissue (MALT) Lymphoma and their status?
What are the key designations that have been granted to the emerging drugs?

Introduction
Executive Summary
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Tafasitamab: Morphosys
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early stage products (Phase I/II)
Comparative Analysis
LOXO-305: Loxo Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Key Companies
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Key Products
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma- Unmet Needs
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma- Market Drivers and Barriers
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma- Future Perspectives and Conclusion
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Analyst Views
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Key Companies
Appendix

List Of Tables

Table 1 Total Products for Mucosa-associated Lymphoid Tissue (MALT) Lymphoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

Figure 1 Total Products for Mucosa-associated Lymphoid Tissue (MALT) Lymphoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available